Exact Mass: 319.1671

Exact Mass Matches: 319.1671

Found 83 metabolites which its exact mass value is equals to given mass value 319.1671, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

1-Carbazol-9-yl-3-(3,5-dimethylpyrazol-1-yl)-propan-2-ol

1-Carbazol-9-yl-3-(3,5-dimethylpyrazol-1-yl)-propan-2-ol

C20H21N3O (319.1685)


   

2-[2-[[4-[[3-Aminopropyl]amino]butyl]amino]-2-oxoethyl]-2-hydroxybutanedioic acid

2-[2-[[4-[[3-Aminopropyl]amino]butyl]amino]-2-oxoethyl]-2-hydroxybutanedioic acid

C13H25N3O6 (319.1743)


   

(2S)-2-Hydroxy-2-(propan-2-yl)butanedioylcarnitine

3-{[3-carboxy-3-hydroxy-3-(propan-2-yl)propanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C14H25NO7 (319.1631)


(2S)-2-hydroxy-2-(propan-2-yl)butanedioylcarnitine is an acylcarnitine. More specifically, it is an (2S)-2-hydroxy-2-(propan-2-yl)butanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2S)-2-hydroxy-2-(propan-2-yl)butanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2S)-2-hydroxy-2-(propan-2-yl)butanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Imidafenacin

4-(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide

C20H21N3O (319.1685)


G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Imidafenacin (KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors.

   

Oxetorone

(3-{9,18-dioxatetracyclo[9.7.0.0^{3,8}.0^{12,17}]octadeca-1(11),3,5,7,12,14,16-heptaen-2-ylidene}propyl)dimethylamine

C21H21NO2 (319.1572)


N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations

   

1,3-Propanediol, 2-((3-fluoranthenylmethyl)amino)-2-methyl-

2-{[(fluoranthen-3-yl)methyl]amino}-2-methylpropane-1,3-diol

C21H21NO2 (319.1572)


   
   
   

Oprea1_820256

Oprea1_820256

C20H21N3O (319.1685)


   

2-Naphthalenol, 1-[[4-(diethylamino)phenyl]azo]-

2-Naphthalenol, 1-[[4-(diethylamino)phenyl]azo]-

C20H21N3O (319.1685)


   

DTXSID801000213

DTXSID801000213

C20H21N3O (319.1685)


   

Macrophylline

Macrophylline

C20H21N3O (319.1685)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

CAY10498

1H-Purine-2,6-diamine, N6-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-N2-phenyl

C18H19N6 (319.1671)


   

4-(3-BENZHYDRYL-1,2,4-OXADIAZOL-5-YL)PIPERIDINE

4-(3-BENZHYDRYL-1,2,4-OXADIAZOL-5-YL)PIPERIDINE

C20H21N3O (319.1685)


   

(5-Isopropoxy-1-{[(2-methyl-2-propanyl)oxy]carbonyl}-1H-indol-2-y l)boronic acid

(5-Isopropoxy-1-{[(2-methyl-2-propanyl)oxy]carbonyl}-1H-indol-2-y l)boronic acid

C16H22BNO5 (319.1591)


   
   

N[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]-SUCCINAMIC ACID

N[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]-SUCCINAMIC ACID

C16H22BNO5 (319.1591)


   

Methenamine hippurate

Methenamine hippurate

C15H21N5O3 (319.1644)


C254 - Anti-Infective Agent > C255 - Urinary Anti-Infective Agent D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

   

Oxetorone

Oxetorone

C21H21NO2 (319.1572)


N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist

   

3,4-DIBENZYLOXYBENZYLAMINE

3,4-DIBENZYLOXYBENZYLAMINE

C21H21NO2 (319.1572)


   

3-(4-Cyanophenyl)propenoic acid 4-pentylphenyl ester

3-(4-Cyanophenyl)propenoic acid 4-pentylphenyl ester

C21H21NO2 (319.1572)


   

Cilansetron

Cilansetron

C20H21N3O (319.1685)


A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AE - Serotonin receptor antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist

   

Tert-Butyl 6-Fluoro-3-Oxo-2,3-Dihydrospiro[Indene-1,4-Piperidine]-1-Carboxylate

Tert-Butyl 6-Fluoro-3-Oxo-2,3-Dihydrospiro[Indene-1,4-Piperidine]-1-Carboxylate

C18H22FNO3 (319.1584)


   

(4-amino-3-methyl-phenyl)-bis(4-aminophenyl)methanol

(4-amino-3-methyl-phenyl)-bis(4-aminophenyl)methanol

C20H21N3O (319.1685)


   

Tesmilifene hydrochloride

Tesmilifene hydrochloride

C19H26ClNO (319.1703)


C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C210 - Immunoadjuvant > C2141 - Chemo Immunostimulant Adjuvant C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent C2140 - Adjuvant

   

1,3-Propanediol, 2-((3-fluoranthenylmethyl)amino)-2-methyl-

1,3-Propanediol, 2-((3-fluoranthenylmethyl)amino)-2-methyl-

C21H21NO2 (319.1572)


C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent

   

[1-(3-Methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone

[1-(3-Methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone

C20H21N3O (319.1685)


   

Imidafenacin

Imidafenacin

C20H21N3O (319.1685)


G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Imidafenacin (KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors.

   

N-citryl-spermidine

N-citryl-spermidine

C13H25N3O6 (319.1743)


   

(2S)-2-Hydroxy-2-(propan-2-yl)butanedioylcarnitine

(2S)-2-Hydroxy-2-(propan-2-yl)butanedioylcarnitine

C14H25NO7 (319.1631)


   

(2S)-2-cyano-1-(4-phenyl-L-phenylalanyl)pyrrolidine

(2S)-2-cyano-1-(4-phenyl-L-phenylalanyl)pyrrolidine

C20H21N3O (319.1685)


   

Leu-Thr-Ser

Leu-Thr-Ser

C13H25N3O6 (319.1743)


A tripeptide composed of L-leucine, L-threonine and L-serine joined in sequence by peptide linkages.

   

1-methyl-N-[4-(4-morpholinyl)phenyl]-2-quinolinimine

1-methyl-N-[4-(4-morpholinyl)phenyl]-2-quinolinimine

C20H21N3O (319.1685)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

3-(2-aminoethyl)-6-methoxy-1H-indol-5-ol;2-amino-3-methyl-4H-imidazol-5-one

3-(2-aminoethyl)-6-methoxy-1H-indol-5-ol;2-amino-3-methyl-4H-imidazol-5-one

C15H21N5O3 (319.1644)


   

(3R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxynonanoate

(3R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxynonanoate

C15H27O7- (319.1757)


   

(3R,8R)-8-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxynonanoate

(3R,8R)-8-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxynonanoate

C15H27O7- (319.1757)


   

3-(2-aminoethyl)-7-methoxy-1H-indol-5-ol;2-amino-3-methyl-4H-imidazol-5-one

3-(2-aminoethyl)-7-methoxy-1H-indol-5-ol;2-amino-3-methyl-4H-imidazol-5-one

C15H21N5O3 (319.1644)


   

4-(2,3-Diacetyloxypropoxy)-2-(trimethylazaniumyl)butanoate

4-(2,3-Diacetyloxypropoxy)-2-(trimethylazaniumyl)butanoate

C14H25NO7 (319.1631)


   

bhas#10(1-)

bhas#10(1-)

C15H27O7 (319.1757)


Conjugate base of bhas#10

   

bhos#10(1-)

bhos#10(1-)

C15H27O7 (319.1757)


Conjugate base of bhos#10

   

1-Carbazol-9-yl-3-(3,5-dimethyl-pyrazol-1-yl)-propan-2-ol

1-Carbazol-9-yl-3-(3,5-dimethyl-pyrazol-1-yl)-propan-2-ol

C20H21N3O (319.1685)


   

Carbazolyldimethyl-pyrazolylpropanol

Carbazolyldimethyl-pyrazolylpropanol

C20H21N3O (319.1685)


   
   

(4e)-7-(chloromethylidene)-n-(2-phenylethyl)dec-4-enimidic acid

(4e)-7-(chloromethylidene)-n-(2-phenylethyl)dec-4-enimidic acid

C19H26ClNO (319.1703)


   

5,9,17,17-tetramethyl-3,8-dioxa-10-azapentacyclo[10.8.0.0²,⁶.0⁷,¹¹.0¹³,¹⁸]icosa-1(12),2(6),4,7(11),9,13(18),19-heptaene

5,9,17,17-tetramethyl-3,8-dioxa-10-azapentacyclo[10.8.0.0²,⁶.0⁷,¹¹.0¹³,¹⁸]icosa-1(12),2(6),4,7(11),9,13(18),19-heptaene

C21H21NO2 (319.1572)


   

7-(chloromethylidene)-n-(2-phenylethyl)dec-4-enimidic acid

7-(chloromethylidene)-n-(2-phenylethyl)dec-4-enimidic acid

C19H26ClNO (319.1703)


   

(4e,7e)-7-(chloromethylidene)-n-(2-phenylethyl)dec-4-enimidic acid

(4e,7e)-7-(chloromethylidene)-n-(2-phenylethyl)dec-4-enimidic acid

C19H26ClNO (319.1703)


   

4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,12-hexaen-20-ol

4,14,20-triazahexacyclo[13.6.2.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁶,²¹]tricosa-2,4,6,8,10,12-hexaen-20-ol

C20H21N3O (319.1685)


   

6-{[(4s,5r,6s,8s,10r)-6-hydroxy-5-methyl-2,11,12-triazatricyclo[6.3.1.0⁴,¹²]dodec-1-en-10-yl]methyl}pyrimidine-2,4-diol

6-{[(4s,5r,6s,8s,10r)-6-hydroxy-5-methyl-2,11,12-triazatricyclo[6.3.1.0⁴,¹²]dodec-1-en-10-yl]methyl}pyrimidine-2,4-diol

C15H21N5O3 (319.1644)


   

5,9,17,17-tetramethyl-3,10-dioxa-8-azapentacyclo[10.8.0.0²,⁶.0⁷,¹¹.0¹³,¹⁸]icosa-1(12),2(6),4,7(11),8,13(18),19-heptaene

5,9,17,17-tetramethyl-3,10-dioxa-8-azapentacyclo[10.8.0.0²,⁶.0⁷,¹¹.0¹³,¹⁸]icosa-1(12),2(6),4,7(11),8,13(18),19-heptaene

C21H21NO2 (319.1572)